NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,338,682 | -20.7% | 2,714,845 | +0.8% | 0.00% | 0.0% |
| Q2 2023 | $26,893,490 | +15.4% | 2,692,041 | +2.6% | 0.00% | 0.0% |
| Q1 2023 | $23,296,281 | -3.7% | 2,623,455 | +19.1% | 0.00% | 0.0% |
| Q4 2022 | $24,184,603 | -14.1% | 2,202,605 | +1.9% | 0.00% | 0.0% |
| Q3 2022 | $28,156,000 | +5.2% | 2,160,866 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $26,754,000 | -5.8% | 2,111,496 | +4.1% | 0.00% | 0.0% |
| Q1 2022 | $28,413,000 | -50.7% | 2,028,063 | +1.9% | 0.00% | 0.0% |
| Q4 2021 | $57,626,000 | -2.8% | 1,990,564 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $59,259,000 | +52.4% | 1,977,951 | +34.9% | 0.00% | 0.0% |
| Q2 2021 | $38,896,000 | +7.6% | 1,466,137 | +26.1% | 0.00% | 0.0% |
| Q1 2021 | $36,156,000 | +77.9% | 1,162,984 | +88.2% | 0.00% | 0.0% |
| Q4 2020 | $20,320,000 | +8.6% | 617,985 | +15.3% | 0.00% | 0.0% |
| Q3 2020 | $18,716,000 | – | 536,120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $18,210,601 | 1.88% |
| DAFNA Capital Management LLC | 556,695 | $5,561,383 | 1.52% |
| Deep Track Capital, LP | 2,997,830 | $29,948,322 | 1.39% |
| Redmile Group, LLC | 2,857,309 | $28,544,517 | 1.10% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,830,497 | 0.80% |
| Boxer Capital, LLC | 1,224,892 | $12,237 | 0.57% |
| AtonRa Partners | 30,142 | $301,119 | 0.47% |
| Affinity Asset Advisors, LLC | 100,000 | $999,000 | 0.35% |
| HARVARD MANAGEMENT CO INC | 314,762 | $3,144 | 0.31% |
| WASATCH ADVISORS LP | 3,869,775 | $38,659,052 | 0.23% |